No Data
Dezhan Healthcare (000813.SZ): has repurchased a total of 1.32% of its shares.
On January 2, Gelonghui reported that Dezhan Healthcare (000813.SZ) announced that as of December 31, 2024, the company has cumulatively repurchased 28,567,500 shares through a dedicated securities account for share repurchase via centralized bidding trade, accounting for 1.32% of the company's current total share capital, with a highest Fill Price of 3.21 yuan/share, a lowest Fill Price of 2.39 yuan/share, and a total amount of 73.2659 million yuan (excluding transaction fees).
Express News | Dezhan Healthcare: The holding subsidiary has obtained the Medical Institutions practice license.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Dezhan Healthcare Ties Up With CAE's Academician Yang Baofeng to Set Up Drug-Developing Workstation
Express News | Dezhan Healthcare: Signed the "Cooperation Framework Agreement" with Yang Baofeng, an academician of the Chinese Academy of Engineering.
Express News | Dezhan Healthcare: Abnormal fluctuations in stock trade, operation situation is normal.
